Reza Zare1, Kazem Anvari2, Farnaz Mohajertehran1,3, Alieh Farshbaf4, Atessa Pakfetrat1, Amir Houshang Ansari5, Maryam Ghelichli6, Nooshin Mohtasham1. 1. Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Radiotherapy Oncology and Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Student research committee, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Department of Oral and Maxillofacial Pathology, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran.
Abstract
Background: The oral squamous cell carcinoma (OSCC) composes about 90% of all head and neck cancers. The toll-like receptor (TLR)+ immune cells have potential of invasion and malignancy transformation. The aim of this study was assessment of possible associations between clinicopathological indices and TLR2 and TLR9 gene expression in OSCC. Methods: Forty-two OSCC samples with related healthy margins including 25 early and 17 advanced stages were gathered. The samples were classified histologically from grade I to II. The expression of TLR2 and TLR2 was evaluated by Real-time PCR. The patient's disease-free survival (DFS) and overall survival (OS) were analyzed using SPSS V.23 software. Results: The expression of TLR2 and TLR9 genes in tumor tissues (especially in grade I and II) were higher than healthy surgical margin tissue (p< 0.001). TLR9 expression in grade II was statistically significant than grade I in tumor tissue (p< 0.001). TLR9 expression in advanced stage was statistically significant in compare to early stage (p= 0.012). In advanced stage both overall survival (p= 0.029) and disease-free survival (p= 0.012) were statistically lower than early stage. The follow-up time to recurrence in advanced stage was statistically lower than early stage (p= 0.007). Conclusion: Overexpression of TLRs 2, 9 play role in the pathogenesis and tumor development of OSCC and can be applied as biomarker in prognostic approaches.
Background: The oral squamous cell carcinoma (OSCC) composes about 90% of all head and neck cancers. The toll-like receptor (TLR)+ immune cells have potential of invasion and malignancy transformation. The aim of this study was assessment of possible associations between clinicopathological indices and TLR2 and TLR9 gene expression in OSCC. Methods: Forty-two OSCC samples with related healthy margins including 25 early and 17 advanced stages were gathered. The samples were classified histologically from grade I to II. The expression of TLR2 and TLR2 was evaluated by Real-time PCR. The patient's disease-free survival (DFS) and overall survival (OS) were analyzed using SPSS V.23 software. Results: The expression of TLR2 and TLR9 genes in tumor tissues (especially in grade I and II) were higher than healthy surgical margin tissue (p< 0.001). TLR9 expression in grade II was statistically significant than grade I in tumor tissue (p< 0.001). TLR9 expression in advanced stage was statistically significant in compare to early stage (p= 0.012). In advanced stage both overall survival (p= 0.029) and disease-free survival (p= 0.012) were statistically lower than early stage. The follow-up time to recurrence in advanced stage was statistically lower than early stage (p= 0.007). Conclusion: Overexpression of TLRs 2, 9 play role in the pathogenesis and tumor development of OSCC and can be applied as biomarker in prognostic approaches.
Authors: Zuzanna Urban-Wojciuk; Mohd M Khan; Benjamin L Oyler; Robin Fåhraeus; Natalia Marek-Trzonkowska; Aleksandra Nita-Lazar; Ted R Hupp; David R Goodlett Journal: Front Immunol Date: 2019-10-22 Impact factor: 7.561
Authors: P Parroche; G Roblot; F Le Calvez-Kelm; I Tout; M Marotel; M Malfroy; G Durand; J McKay; M Ainouze; C Carreira; O Allatif; A Traverse-Glehen; M Mendiola; J J Pozo-Kreilinger; C Caux; M Tommasino; N Goutagny; U A Hasan Journal: Oncogenesis Date: 2016-07-25 Impact factor: 7.485